Loading page…

Ngl Fine-Chem Limited (NGLFINE) · mywealthgrid

About

Ngl Fine-Chem is a mid-cap pharmaceutical company (₹2,141.48 Cr market cap) with quarterly revenues of ₹116–149 Cr and operating margins between 11.69% and 17.5%. The stock has appreciated 180.95% over one year, though this surge outpaces visible revenue growth in recent quarters.

Face value: ₹5

Market cap

₹1,813 Cr

P/E

31.7×

P/B

5.5×

Dividend yield

0.1%

ROE

15.7%

ROCE

19.1%

Debt / equity

0.33

OPM

14.5%

EPS (TTM)

₹92.6

Book value

₹532.7

52-week high

₹3,457.8

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation at PE 37.43 with 180.95% appreciation appears driven by revaluation rather than visible revenue growth (₹116–149 Cr range); verify if earnings trajectory justifies the multiple
Operating margin volatility (11.69%–17.5%) and net profit swings (₹7.9–18.4 Cr) on stable revenue signal operational or cost inconsistency; verify root causes and durability of recent recovery
Minimal institutional investor presence (FII 0.05%, DII 0.02%) suggests analyst coverage gap or institutional skepticism; verify sell-side research and investor sentiment
Pharmaceutical sector exposed to regulatory pressures, generic competition, and pricing controls; verify company's competitive positioning and sector hedges

Generated analysis · source review pending

Growth drivers

Operating margins recovered from 11.69% (Sep 2025) to 14–17.5% in recent quarters; verify if driven by volume, pricing, or cost relief and whether sustainable
EPS growth from ₹12.78 (Sep 2025) to ₹26.63–29.78 recently; verify if reflecting operational improvement or driven by profit volatility
Low debt-to-equity ratio (0.33) provides capacity for growth capex or acquisitions; verify capex roadmap and capital allocation strategy
Revenue base at ₹116–149 Cr with ROE 15.74% provides platform for profitable growth; verify market opportunities and expansion plans

Generated analysis · source review pending

₹2,924.0+110.6%1Y

Beta

1.18

Moves with the index

Volatility (1y)

57.2%

Annualised, daily returns

RSI (14)

60.2

Neither overbought nor oversold

Rel. strength (1y)

98%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Comfortable interest coverage of 15.2×
+High promoter holding of 72.5% with no pledge
+Outperformed the universe by 98% over 1 year

Cons

−Profit declined 3.2% a year over the last 5 years
−Low dividend payout of 1.9% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

70/100

Business quality: 61
Growth: 97
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	258	318	278	339	368	501
COGS	102	147	140	159	182	239
Gross profit	156	171	138	180	186	261
	76	103	103	127	152	189
	80	68	34	53	34	73
OPM %	30.9%	21.4%	12.3%	15.7%	9.2%	14.5%
Depreciation	8	10	11	12	12	20
Interest	2	2	1	1	2	4
	8	11	6	14	9	15
Profit before tax	78	67	27	54	28	63
Tax	21	17	7	13	7	15
Tax %	26.9%	25.1%	25.1%	24.1%	23.8%	24.1%
	57	50	21	41	21	48
PAT margin %	22%	15.7%	7.4%	12.2%	5.7%	9.6%
EPS (₹)	—	—	33.2	66.9	34.2	77.9
EPS adjusted (₹)	91.8	80.7	33.2	66.9	34.2	77.9
	—	—	5.3%	2.6%	5.1%	2.2%
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3
Reserves	151	200	219	260	279	326
	11	27	30	32	73	108
	42	47	34	60	78	108
Total equity & liabilities	207	277	287	356	433	546
	64	89	88	86	143	164
CWIP	12	6	26	46	50	95
Investments	29	29	39	54	60	39
	102	153	133	171	181	248
Total assets	207	277	287	356	433	546

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	27	14	35	20	36	43
	-25	-14	-27	-27	-35	-71
	-1	-1	-1	-1	-1	30
Net cash flow	2	-1	7	-7	0	2
Free cash flow	10	-43	4	-8	-95	-47
CFO / Operating profit %	34.3%	20.4%	102.8%	38.4%	105.8%	59.6%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	60.3%	53.7%	49.5%	53.1%	50.5%	52.2%
EBITDA margin %	30.9%	21.4%	12.3%	15.7%	9.2%	14.5%
EBIT margin %	27.7%	18.1%	8.3%	12.3%	5.8%	10.6%
PAT margin %	22%	15.7%	7.4%	12.2%	5.7%	9.6%
Working capital
Receivable days	53	74	86	97	81	95
Inventory days	135	139	70	100	103	107
Payable days	105	92	64	114	115	98
NWC days	83	120	93	83	68	104
Leverage
Current ratio	2.98	2.64	2.79	2.46	1.98	1.84
Debt to EBITDA	0.14	0.4	0.89	0.61	2.16	1.49
Debt to equity	0.07	0.13	0.14	0.12	0.26	0.33
Interest coverage	43.2	43.7	23.8	41.6	12.9	15.2
Asset turnover	1.24	1.15	0.97	0.95	0.85	0.92
Return ratios
Return on assets %	27.3%	18%	7.1%	11.6%	4.9%	8.8%
Return on capital employed %	48%	36.2%	13%	22.4%	10.3%	19.1%
Return on equity %	36.7%	24.6%	9.2%	15.7%	7.5%	14.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	73.06%	73.06%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.49%
	0.02%	0.04%	0.1%	0.03%	0.02%	0.04%	0%	0%	0%	0%	0.03%	0.05%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.02%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	26.92%	26.9%	27.16%	27.23%	27.24%	27.22%	27.26%	27.26%	27.26%	27.26%	27.23%	27.44%
No. of shareholders	—	—	—	—	—	—	—	—	13,387	12,834	12,516	13,393

Promoter holding down 0.57 percentage points since Sep 2023.

Mr. DHANANJAY MUNGALENon-Executive - Independent Director-Chairperson
Mr. RAHUL NACHANEExecutive Director-MD
Mr. RAJESH LAWANDEExecutive Director
Mrs. AJITA NACHANENon-Executive - Non Independent Director
Mr. SUDHIR DEONon-Executive - Independent Director
Mrs. SARALA MENONNon-Executive - Independent Director
Mr. Shivam GharatCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Ngl Fine-Chem Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Intimation of revision in credit rating pursuant to Regulation 30 of SEBI (Listing Oblignation and Disclsoure Requirement) Regulations, 201513 Mar 2026

Investor Presentation and earnings call

May 2026Transcript AI Summary PPT REC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

9

Final dividend18 Aug 2026 · ex-date₹1.75
Final dividend12 Aug 2025 · ex-date₹1.75
Final dividend16 Aug 2024 · ex-date₹1.75
Final dividend18 Aug 2023 · ex-date₹1.75
Final dividend22 Jun 2022 · ex-date₹1.75
Dividend dividend12 Aug 2021 · ex-date₹1.75
Final dividend6 Aug 2020 · ex-date₹1.75
Final dividend13 Aug 2019 · ex-date₹1.75
Final dividend8 Aug 2007 · ex-date₹0.5

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

57 announcementsExport CSV

28 Sept 2026, 5:18 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Date	Category	Subject	Filing
28 Sept 2026, 5:18 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
16 Sept 2026, 3:07 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
10 Sept 2026, 5:51 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
27 Aug 2026, 5:52 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
25 Aug 2026, 9:47 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
20 Aug 2026, 3:06 pm	Company Update General	Corrigendum To The 45Th Annual Report For The Financial Year 2025-2026	PDF
17 Aug 2026, 2:52 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF
14 Aug 2026, 3:06 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

Ngl Fine-Chem Limited

Ngl Fine-Chem Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends9

Board meetings1

Announcements

Dividends9

Board meetings1

Ratio timeline

Quarterly record

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

9

1

9

1